Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats
- PMID: 22851661
- DOI: 10.1093/ejcts/ezs312
Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats
Abstract
Objectives: The aim of this study was to assess the possible protective effect of montelukast against haemorrhagic shock-induced acute lung injury by interfering with inflammatory and oxidative pathways. Acute lung injury following haemorrhagic shock/resuscitation is an important contributor to late morbidity and mortality in trauma patients. Haemorrhagic shock (HS), followed by resuscitation, is considered to be an insult that frequently induces systemic inflammatory response syndrome and oxidative stress, resulting in multiple-organ dysfunction syndrome, including microvascular changes and microscopic damage termed acute lung paraynchymal injury. Montelukast is a cysteinyl leukotriene receptor antagonist that exerts an anti-inflammatory and antioxidant influence.
Methods: Eighteen adult albino rats were assigned to three groups of six. In Group I, the 'sham' group, rats underwent all the surgical procedures but neither haemorrhagic shock nor resuscitation was carried out. Group II--the 'HS' induced, untreated group--was the control and underwent HS for one hour before being resuscitated with Ringer's lactate for one hour. Group III--the 'montelukast' group--underwent HS and treatment with montelukast (7 mg/kg i.p. injection) 30 min before the induction of HS, with the same dose repeated just before the reperfusion period. At the end of the experiment, two hours after completion of resuscitation, blood samples were collected for measurement of serum tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6). The trachea was then isolated and bronchoalveolar lavage was carried out for measurement of leukotriene B(4) (LTB(4)), leukotriene C(4) (LTC(4)) and total protein. The lungs were harvested and the left lung was homogenized for measurement of malondialdehyde (MDA) and reduced glutathione (GSH) and the right lung was fixed in 10% formalin for histological examination.
Results: Montelukast treatment (Group III) significantly reduced the total lung injury score, compared with the HS group (Group II) (P < 0.05). Montelukast also significantly decreased serum TNF-α and IL-6; lung MDA; bronchoalveolar lavage fluid (BALF) LTB(4), LTC(4) & total protein compared with the HS group (P < 0.05). Montelukast treatment significantly inhibited decrease in the lung GSH levels, compared with the HS group (P < 0.05).
Conclusions: The results of the present study reveal that montelukast may ameliorate lung injury in shocked rats by interfering with inflammatory and oxidative pathways, implicating the role of leukotrienes in the pathogenesis of haemorrhagic shock-induced lung inflammation.
Similar articles
-
Leukotriene biosynthesis inhibition ameliorates acute lung injury following hemorrhagic shock in rats.J Cardiothorac Surg. 2011 Jun 7;6:81. doi: 10.1186/1749-8090-6-81. J Cardiothorac Surg. 2011. PMID: 21649921 Free PMC article.
-
Chronic renal failure-induced multiple-organ injury in rats is alleviated by the selective CysLT1 receptor antagonist montelukast.Prostaglandins Other Lipid Mediat. 2007 Jun;83(4):257-67. doi: 10.1016/j.prostaglandins.2007.01.013. Epub 2007 Jan 20. Prostaglandins Other Lipid Mediat. 2007. PMID: 17499745
-
Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.Eur J Pharmacol. 2007 Feb 14;557(1):69-75. doi: 10.1016/j.ejphar.2006.11.009. Epub 2006 Nov 10. Eur J Pharmacol. 2007. PMID: 17173892
-
A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241232284. doi: 10.1177/17534666241232284. Ther Adv Respir Dis. 2024. PMID: 38504551 Free PMC article. Review.
-
The leukotriene receptor antagonist montelukast and its possible role in the cardiovascular field.Eur J Clin Pharmacol. 2017 Jul;73(7):799-809. doi: 10.1007/s00228-017-2242-2. Epub 2017 Apr 4. Eur J Clin Pharmacol. 2017. PMID: 28374082 Review.
Cited by
-
Zafirlukast ameliorates lipopolysaccharide and bleomycin-induced lung inflammation in mice.BMC Pulm Med. 2024 Sep 16;24(1):456. doi: 10.1186/s12890-024-03273-6. BMC Pulm Med. 2024. PMID: 39285346 Free PMC article.
-
Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence.Front Pharmacol. 2020 Sep 4;11:1344. doi: 10.3389/fphar.2020.01344. eCollection 2020. Front Pharmacol. 2020. PMID: 33013375 Free PMC article.
-
Injured liver-released miRNA-122 elicits acute pulmonary inflammation via activating alveolar macrophage TLR7 signaling pathway.Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6162-6171. doi: 10.1073/pnas.1814139116. Epub 2019 Mar 13. Proc Natl Acad Sci U S A. 2019. PMID: 30867286 Free PMC article.
-
Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: A double-blind, randomized clinical trial.Chin J Traumatol. 2023 Mar;26(2):116-120. doi: 10.1016/j.cjtee.2022.10.002. Epub 2022 Oct 13. Chin J Traumatol. 2023. PMID: 36357273 Free PMC article. Clinical Trial.
-
Role of cysteinyl leukotriene signaling in a mouse model of noise-induced cochlear injury.Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9911-6. doi: 10.1073/pnas.1402261111. Epub 2014 Jun 23. Proc Natl Acad Sci U S A. 2014. PMID: 24958862 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous